About the Polymyalgia Rheumatica Working Group

Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by subacute onset pain and stiffness in the shoulders and hips. Oral glucocorticoids represent the mainstay of treatment and while cessation of therapy is the ultimate goal, up to 50% of patients with PMR continue to require prednisolone 2–3 years after diagnosis.

In 2016, the Outcome Measures in Rheumatology (OMERACT) endorsed a core domain set for PMR. The inner core of the “onion,” signifying items to be measured in all PMR clinical trials, consisted of 4 domains: pain, stiffness, physical function, and systemic inflammation.

catherine hill

Catherine Hill

Co-Chair

sarah mackie

Sarah Mackie

Co-Chair

claire owen

Claire Owen

Co-Chair

Lee Simon

Lee Simon

Co-Chair

OMERACT Endorsed Core Domain Set for Polymyalgia Rheumatica

Screen Shot 2021-02-23 at 10.26.34 AM

Working Group Members:

Rachel Black
Maarten Boers
Elizabeth Brouwer
Frank Buttgereit
Ricardo Jorge de Oliviera Ferreira
Cátia Duarte
Susan Goodman
Serena Halls
Eileen Harrison

Toby Helliwell
Catherine Hill
Rodney Hughes
Tanaz Kermani
John Kirwan
Jessica Leung
Christian Mallen
Sarah Mackie
Eric Matteson
Peter Merkel

Chetan Muktyar
Lorna Neill
Claire Owen
Colin Pease
José António Pereira da Silva
Lee Simon
Bev Shea
Helen Twohig
Peter Tugwell
Max Yates

Scroll to Top